Skip to content
Peptigraph home

IGF-1 LR3 vs CJC-1295 + Ipamorelin: What the Research Shows

IGF-1 LR3 and CJC-1295 + Ipamorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
IGF-1 analogNot FDA approved · research chemicalIGF-1 LR3IGF-1 LR3, a long-acting IGF-1 analog with no published human trial; in rats it was 2.5 to 3 times more potent than IGF-I at restoring growth.[12]Growth hormone+230% searchesGHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[13]Growth hormone+153% searchesPre-mixed blend
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider IGF-1 LR3 if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

Consider CJC-1295 + Ipamorelin if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

  • Only animal or lab studies of IGF-1 LR3 were found (e.g. rat): The IGF-I variants were 2.5-3 times more potent than IGF-I at restoring growth in diabetic rats.[12]
Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldIGF-1 LR3CJC-1295 + Ipamorelin
ClassIGF-1 analogGHRH + GHRP blend
Also calledLR3CJC/Ipa
FDA statusNot FDA approved · research chemicalNot FDA approved · research blend
WADAProhibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times.Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.
Anti-doping detectionNone reportedanti-doping literature, as of 2 Oct 2026
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
Half-life563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Evidence strengthHuman observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030
Human studies we summarised1 human (0 randomized or controlled) of 12 summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients
Typical study doses
Vial sizes sold0.1 mg, 1 mg10 mg
US searches per month22,200 · +230% searches49,500 · +153% searches

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

IGF-1 LR3 and CJC-1295 + Ipamorelin together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

Open the stack page
StackIGF-1 LR3 + CJC-1295 + Ipamorelin, taken as separate injectionsStack page

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
  3. 3Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
  4. 4IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
  5. 5Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
  6. 6Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
  7. 7Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  8. 8Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  9. 9Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  10. 10Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  11. 11PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab])))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
  13. 13Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.